De Burlo Group’s AbbVie ABBV Stock Holding History

De Burlo Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.73M	Sell	26,339 -250	-0.9%	-$55.5K	1.3%	25
2025 Q4	$6.08M	Sell	26,589 -350	-1%	-$79.7K	0.74%	33
2025 Q3	$6.24M	Buy	26,939 +62	+0.2%	+$12.6K	0.75%	34
2025 Q2	$4.99M	Sell	26,877 -744	-3%	-$138K	0.66%	34
2025 Q1	$5.79M	Sell	27,621 -300	-1%	-$58.3K	0.85%	31
2024 Q4	$4.96M	Sell	27,921 -2,230	-7%	-$410K	0.66%	37
2024 Q3	$5.95M	Sell	30,151 -1,000	-3%	-$187K	0.73%	36
2024 Q2	$5.34M	Sell	31,151 -990	-3%	-$164K	0.72%	34
2024 Q1	$5.85M	Sell	32,141 -1,075	-3%	-$185K	0.78%	35
2023 Q4	$4.95M	Hold	33,216	–	–	0.86%	32
2023 Q3	$4.95M	Sell	33,216 -200	-0.6%	-$29.4K	0.86%	32
2023 Q2	$4.5M	Buy	33,416 +100	+0.3%	+$14.7K	0.75%	40
2023 Q1	$5.31M	Sell	33,316 -300	-0.9%	-$45.9K	1.04%	32
2022 Q4	$5.43M	Sell	33,616 -600	-2%	-$92K	1.21%	28
2022 Q3	$4.59M	Buy	34,216 +22,778	+199%	+$3.27M	1.09%	26
2022 Q2	$1.75M	Sell	11,438 -22,978	-67%	-$3.51M	0.5%	22
2022 Q1	$5.58M	Sell	34,416 -800	-2%	-$116K	1.04%	29
2021 Q4	$4.77M	Buy	35,216 +933	+3%	+$110K	0.69%	45
2021 Q3	$3.7M	Buy	34,283 +33	+0.1%	+$3.77K	0.6%	48
2021 Q2	$3.86M	Hold	34,250	–	–	0.61%	42
2021 Q1	$3.71M	Sell	34,250 -100	-0.3%	-$10.7K	0.66%	42
2020 Q4	$3.68M	Buy	34,350 +2,400	+8%	+$231K	0.6%	41
2020 Q3	$2.8M	Sell	31,950 -100,350	-76%	-$9.45M	0.51%	45
2020 Q2	$10.1M	Hold	132,300	–	–	2.83%	15
2020 Q1	$10.1M	Buy	132,300 +100,950	+322%	+$8.6M	2.83%	15
2019 Q4	$2.78M	Sell	31,350 -1,400	-4%	-$116K	0.56%	43
2019 Q3	$2.48M	Sell	32,750 -800	-2%	-$54.8K	0.56%	41
2019 Q2	$2.44M	Sell	33,550 -200	-0.6%	-$15.7K	0.48%	47
2019 Q1	$2.72M	Sell	33,750 -1,600	-5%	-$131K	0.55%	48
2018 Q4	$3.26M	Sell	35,350 -200	-0.6%	-$17.6K	0.73%	39
2018 Q3	$3.36M	Hold	35,550	–	–	0.63%	49
2018 Q2	$3.29M	Sell	35,550 -20,500	-37%	-$2M	0.7%	38
2018 Q1	$5.3M	Buy	56,050 +20,500	+58%	+$2.25M	1.16%	31
2017 Q4	$3.44M	Sell	35,550 -125	-0.4%	-$11.8K	0.7%	45
2017 Q3	$3.17M	Hold	35,675	–	–	0.7%	40
2017 Q2	$2.59M	Buy	35,675 +125	+0.4%	+$8.4K	0.58%	42
2017 Q1	$2.32M	Sell	35,550 -45,100	-56%	-$2.84M	0.5%	51
2016 Q4	$5.05M	Sell	80,650 -41,900	-34%	-$2.56M	1.23%	34
2016 Q3	$7.73M	Buy	122,550 +2,740	+2%	+$177K	2.14%	12
2016 Q2	$7.42M	Buy	119,810 +51,100	+74%	+$3.11M	1.79%	21
2016 Q1	$3.92M	Buy	68,710 +38,000	+124%	+$2.12M	1.14%	39
2015 Q4	$1.82M	Sell	30,710 -27,100	-47%	-$1.56M	0.43%	62
2015 Q3	$3.15M	Sell	57,810 -57,600	-50%	-$3.75M	0.74%	49
2015 Q2	$7.75M	Buy	115,410 +8,823	+8%	+$576K	1.62%	23
2015 Q1	$6.24M	Sell	106,587 -80,700	-43%	-$4.88M	1.24%	36
2014 Q4	$12.3M	Buy	187,287 +18,600	+11%	+$1.17M	2.48%	8
2014 Q3	$9.74M	Buy	168,687 +1,510	+0.9%	+$83.8K	2.15%	14
2014 Q2	$9.44M	Buy	167,177 +51,977	+45%	+$2.73M	2.14%	15
2014 Q1	$5.92M	Sell	115,200 -2,200	-2%	-$111K	1.43%	30
2013 Q4	$6.2M	Buy	117,400 +12,000	+11%	+$590K	1.48%	29
2013 Q3	$4.71M	Buy	105,400 +100,500	+2,051%	+$4.45M	1.28%	37
2013 Q2	$203K	Buy	+4,900	New	+$214K	0.06%	89

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

De Burlo Group's ABBV Position: Q1 2026 in Review

De Burlo Group reduced its AbbVie (ABBV) stake by 0.94% in Q1 2026, selling an estimated $55.5K and leaving 26,339 shares worth $5.73M. The position accounts for 1.3% of the portfolio, ranked #25.

De Burlo Group first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $12.3M in Q4 2014. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

De Burlo Group held 26,339 shares of AbbVie worth $5.73M as of Q1 2026.
De Burlo Group sold 250 AbbVie shares in Q1 2026, an estimated $55.5K.
AbbVie made up 1.3% of De Burlo Group's portfolio in Q1 2026, its #25 holding.
De Burlo Group first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
De Burlo Group's AbbVie position peaked at $12.3M in Q4 2014.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on De Burlo Group's 13F filing for Q1 2026, filed 14 May 2026.